Previous studies have shown that DCAF13 is amplified in various tumors, such as hepatocellular carcinoma (Cao et al., 2017), breast cancer (Wang et al., 2019), and osteosarcoma (Chen et al., 2018). Here, DCAF13 is linked to breast cancer.